Viking Therapeutics (VKTX) Q3 2026 earnings review
Viking's monthly doses kept weight off, but spending hit a record
Viking's obesity drug held its effect at less frequent doses, while the cost of proving it reached a new high. Patients moved from weekly to monthly VK2735 shots kept most of their weight loss, which chief executive Brian Lian called "an impressive maintenance effect". Operating expenses rose 41% from the second quarter; a $575 million stock and note sale paid for it.
| Cash and short-term investments | $960M $502M at the end of June, after a $575M stock and note sale |
|---|---|
| Operating expenses | $187.1M +41% from the second quarter |
| Weight loss kept on monthly doses | 82–90% 61% for patients moved to placebo |
| Injectable Phase 3 data | Second half of 2027 unchanged |
⚖️ Verdict: 🟢 Bullish
The story got better because the maintenance study answered the main question about dosing flexibility and the oral Phase 3 trials started on time. The bad news: spending did not peak in the second quarter as finance chief Greg Zante suggested. Funding it cost 9% more shares and $250 million of convertible debt.
The question now is whether monthly dosing reaches the label before the injectable data arrive next year. Either the 2027 extension studies carry it into the approval filing, or it needs its own longer trial, as Lian said last year. The extension studies' design will tell.
🐂 Bull Case
Less Frequent Doses Kept the Weight Off
Viking's lead drug VK2735 is a weekly injection that copies two gut hormones, GLP-1 and GIP, to curb appetite. The San Diego drug developer wants patients to lose weight on weekly shots and then keep it off on smaller or rarer doses. That matters because most patients stop obesity drugs within a year, the company's presentation says. Chief executive Brian Lian said the study showed "an impressive maintenance effect, excellent tolerability".
In the 180-patient study, patients lost up to about 19% of their body weight after 21 weekly doses. Viking then switched them to every-other-week or monthly shots for a further 12 weeks, or to placebo, and measured how much of the loss they kept.
- Weight loss kept at week 33, every-other-week doses: 83% to 97%
- Weight loss kept at week 33, monthly doses: 82% to 90%
- Weight loss kept, patients moved to placebo: 61%
- Weight loss on continued 17.5 mg weekly dosing: about 22% at week 33, with no plateau
This matters because a drug that holds weight on fewer doses gives Viking a product no rival sells today. It says no other dual or triple agonist comes as both a tablet and an injection, and Lian said the pair will offer "unmatched optionality and flexibility". The placebo arm tests that claim: those patients gave back nearly 40% of their loss by our math, so VK2735 is doing the work.
What to watch: the doses Viking selects for the VANQUISH extension studies, which start in the first quarter of 2027. Monthly or every-other-week arms there would put maintenance dosing on the path to the product label.
Side Effects Reported Separately for Each Study Phase
On the second-quarter call, chief executive Brian Lian told analysts, "We compressed the titration blocks in that first 21-week treatment period." Faster dose increases usually mean more nausea, so a readout that blended the two phases could have hidden how patients fared on the rarer doses. The October presentation reports the phases separately.
During induction, 40% of treated patients reported mild nausea and 27% vomited. The placebo rate for each was 7%, so the quicker step-ups did cost some comfort early on. After the switch to every-other-week doses, 5% reported mild nausea and 3% vomited. Viking said these patients "did not resensitize to GI adverse events such as nausea or vomiting". Overall adverse events in that phase ran at 38%, below the 52% on placebo.
What to watch: dropouts in the VANQUISH extension studies after patients move to less frequent doses, with results due in 2028. A rate near the 5% seen on monthly doses in this study would confirm the tolerability the smaller trial showed.
Oral Phase 3 Started on Time With Smaller Trials
Viking is also developing VK2735 as a daily tablet, which it wants to be "the first oral dual GLP-1/GIP agonist to reach the market". After one slip from the third quarter to the fourth, the SUNRISE Phase 3 programme began in October, on the revised schedule.
The two SUNRISE studies each target 560 adults for 68 weeks, one in obesity and one in obesity with type 2 diabetes. By our math the oral programme enrols about 80% fewer patients than the injectable VANQUISH trials, so it costs far less to run. Chief executive Brian Lian said on the second-quarter call the oral trials would be "75% smaller than the VANQUISH study".
- VANQUISH-1 and -2 (injection): about 4,500 and 1,000 patients, 78 weeks of dosing, data in the second half of 2027
- SUNRISE-1 and -2 (tablet): 560 patients each, 68 weeks of dosing, data in 2028
- Maintenance Part 2 (injection, then tablet): about 195 patients, results in 2027
- VK3019 (amylin-based drug): single-dose study finishing this quarter, multiple-dose study in the first quarter of 2027
This matters because a daily pill of the same molecule lets a patient start on injections and continue on tablets without changing drugs, which Viking argues lowers the risk of new side effects. But the 2028 readout puts the tablet on the market well after the injection, and the company has not said how many tablets each Phase 3 dose requires.
What to watch: how fast SUNRISE fills its 1,120 places. VANQUISH-1 enrolled its 4,500 patients in about five months. A similar pace would keep the 2028 readout date intact.
🐻 Bear Case
Spending Hit a Record After One Quarter's Dip
Finance chief Greg Zante said on the second-quarter call, "I think this is really the heaviest usage period." The third quarter proved otherwise. Operating expenses rose 41% from the second quarter to $187.1 million, the most Viking has ever spent in three months. Research and development drove the rise, and the company blamed clinical studies, drug manufacturing, stock-based compensation and salaries.
- Research and development: $166.8 million, up 44% from the second quarter
- Net loss per share: $1.55, against $0.81 a year ago
- Cash used before the financing: about $92 million by our math, down from $101 million in the second quarter
Cash use fell even as spending rose, but only because Viking left more bills unpaid. Accounts payable and accrued costs grew $24 million in the quarter, and stock awards cost nothing in cash. Those bills come due, so the cash figure flatters the spending figure. The budget also has further to climb, because the SUNRISE oral trials began in October and Part 2 of the maintenance study has only just started.
What to watch: fourth-quarter operating expenses. A figure above $187 million would mean the oral trials have added a new layer of cost on top of the injectable programme rather than replacing it.
Viking Sold 11 Million Shares and Convertible Notes
Viking funds itself by selling shares, and in September it sold a lot of them. The company closed concurrent offerings of common stock and convertible senior notes for gross proceeds of about $575 million, or about $550 million after costs. Chief executive Brian Lian said the money provides "the runway to execute multiple Phase 3 trials and build the infrastructure to execute a strong and effective commercial strategy".
- Shares outstanding: 127.5 million, up 9.3% in the quarter
- Convertible notes: $250.7 million, the first borrowing beyond office leases
- Cash and short-term investments: $960 million, up from $502 million at the end of June
The money settles the question of whether Viking would raise cash before the injectable data arrive in the second half of 2027. It did. By our math the new balance covers about ten quarters at the third quarter's rate of cash use, which reaches into early 2029, past both the injectable and the oral readouts. The cost is that existing holders now own about 8.5% less of any future VK2735 sales, before the notes convert into more shares.
What to watch: the conversion price and coupon of the notes in the quarterly filing, and whether fourth-quarter cash use stays near $92 million. A higher figure would shorten those ten quarters by our math and bring the next financing forward.
Risks this quarter didn't answer
Four standing concerns received no new information in the third-quarter release or the October investor presentation, so they carry over unchanged into the next quarter.
- Ligand license dispute over liver drug VK2809 and rare-disease drug VK0214: neither document mentions it, though the presentation still lists both assets with "Partnering discussions ongoing"; the quarterly filing's legal note will show its status.
- Cardiovascular outcomes trial: still no plan for a heart-outcomes study of VK2735, which rival drugmakers use to win insurance coverage; any trial announcement would set its cost and timing.
- Manufacturing prepayments to CordenPharma, due between 2026 and 2028: the release gives no schedule; the filing's commitments note will show how much of the $960 million is already committed.
- Oral drug competition: the SUNRISE doses of 27.5 mg to 55 mg are set, but Viking has not compared the tablet's planned profile with the oral drugs already on sale; the first SUNRISE presentation would do so.
👓 Other Themes
Administrative Costs Rise as Viking Builds a Sales Organisation
General and administrative costs reached $20.3 million, more than double a year ago, on legal and patent work, consultants, stock awards and salaries. Viking said the September financing will support its "growing commercial operations, infrastructure and plans" ahead of a possible VK2735 launch. The company has not said when it will file for approval, so this organisation is a cost without a date.
💲 Other KPIs
Unpaid bills and accrued trial costs rose again, to $133.9 million by our math from $109.5 million at the end of June. They have grown every quarter for a year and now equal about 72% of a quarter's operating expenses. Those sums will leave the cash balance in coming quarters.
Upfront deposits for clinical studies fell by a third from June's $15.0 million as the maintenance study wound down and Viking drew on the prepayments. The balance is still above the $8.1 million at the end of 2025, and the fourth quarter will show whether the SUNRISE start requires fresh deposits.
Interest earned on cash fell 48% from a year ago to $4.0 million, the fifth straight quarterly decline, because the balance shrank through September before the offering refilled it. A first $88,000 of interest expense on the new convertible notes appeared this quarter, and the fourth quarter will show the full coupon.
🔮 Guidance
Raised. With $960 million in the bank, Viking now says it can fund multiple Phase 3 trials, its earlier programmes and a commercial organisation; three months ago the message was cash into 2028. By our math the balance lasts about ten quarters at the third quarter's cash use, into early 2029. At the full operating-expense rate it would last just over five quarters.
Unchanged. Both injectable Phase 3 studies stay on course to finish in 2027, with data in the second half, after the last patients complete 78 weeks of dosing. The presentation keeps the same date as before, and the release says both studies "continued to advance on track".
New. Patients finishing the 78-week VANQUISH trials can enrol in extension studies for up to 52 more weeks, starting in the first quarter of 2027, with results in 2028. The VANQUISH-1 extension will include every-other-week and monthly dosing, so it is where the maintenance data first reach a registration-size population.
New. The oral Phase 3 trials run 68 weeks, so data arrive in 2028, about a year after the injectable results. The gap means the tablet, which Viking describes as a key differentiating feature, cannot be in the first approval filing unless the company waits for it.
Unchanged, with a wider window. Viking now says results from Part 2, which moves patients from weekly injections to daily tablets, will arrive in 2027; earlier this year it said the first half of 2027. The study enrols about 195 adults, and the oral maintenance doses are the ones that matter for a pill-only regimen.
Unchanged. The single-dose study of VK3019, Viking's amylin-based obesity drug, finishes this quarter, and a four-week multiple-dose study starts in the first quarter of 2027. Lian had pointed to single-dose data later in 2026, so the timetable holds; the presentation lists the next study simply as 2027.
❓ Key Questions
How many tablets will each SUNRISE dose require?
Lian targeted no more than two tablets at higher doses after Phase 2 patients disliked taking four. The release lists the Phase 3 doses in milligrams only, so the tablet count that decides convenience remains unknown.
What was operating cash flow in the third quarter?
The release omits the cash flow statement. Our $92 million cash-use figure depends on the approximate $550 million net proceeds, so the quarterly filing's operating cash flow line is needed to confirm it.
What are the convertible notes' coupon and conversion price?
The balance sheet shows $250.7 million of notes and a first $88,000 of interest expense, but the release gives no coupon, conversion price or maturity. Those terms set the future dilution and the cash interest cost.
Which maintenance doses enter the VANQUISH extensions?
The 10 mg every-other-week arm kept 97% of weight loss, the best result. Lian said last spring that several arms would be chosen; naming them, and whether 10 mg is one, will show how the data shape the label strategy.
When do the CordenPharma prepayments fall due?
Viking committed to multi-year capacity prepayments between 2026 and 2028. Without a schedule, readers cannot tell how much of the $960 million is already committed to manufacturing rather than trials.